A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma
Latest Information Update: 02 Feb 2022
Price :
$35 *
At a glance
- Drugs Pralatrexate (Primary) ; Cobalamin; Folic acid
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Mundipharma (China) Pharmaceutical
- 14 Dec 2021 Results of efficacy and safety of pralatrexate by using data from four trials including this trial presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 06 Sep 2019 Status changed from active, no longer recruiting to completed.
- 23 Mar 2019 Primary endpoint (Objective Response Rate(ORR) by International Working Group Criteria) has been met, according to the results published in the Targeted Oncology